comparemela.com

Latest Breaking News On - Enanta pharmaceuticals price performance - Page 1 : comparemela.com

Federated Hermes Inc. Acquires New Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Federated Hermes Inc. acquired a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 133,189 shares of the biotechnology company’s stock, valued at approximately $1,253,000. Federated Hermes Inc. owned approximately 0.63% […]

Enanta Pharmaceuticals (NASDAQ:ENTA) Rating Lowered to Sell at StockNews.com

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Saturday. Separately, JPMorgan Chase & Co. decreased their target price on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock […]

StockNews.com Downgrades Enanta Pharmaceuticals (NASDAQ:ENTA) to Sell

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday. Separately, JPMorgan Chase & Co. lowered their target price on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” […]

Enanta Pharmaceuticals (NASDAQ:ENTA) Releases Earnings Results, Beats Estimates By $0.78 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) announced its quarterly earnings data on Monday. The biotechnology company reported ($1.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.11) by $0.78, MarketWatch Earnings reports. The business had revenue of $18.93 million for the quarter, compared to analyst estimates of $17.93 million. Enanta Pharmaceuticals […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.